Tower Research Capital LLC (Trc) Actinium Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,547 shares of ATNM stock, worth $10,979. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,547
Previous 3,978
139.99%
Holding current value
$10,979
Previous $7,000
71.43%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ATNM
# of Institutions
70Shares Held
8.26MCall Options Held
79.6KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.62MShares$1.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$791,0300.0% of portfolio
-
State Street Corp Boston, MA621KShares$714,2360.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$574,1490.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $29M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...